Burlington, MA – August 15, 2017 – Decision Resources Group (DRG), the life sciences industry’s most trusted provider of market intelligence and global data products and services, today announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform. Previously the lead investor in a Series B funding round for the startup last fall, DRG’s full acquisition and planned integration of Context Matters cements its position as the partner of choice for global market access data products, analytics, and strategic guidance.
In an interview with PM360, Founder and CEO of Context Matters, Yin Ho, M.D., M.B.A., provides her perspective on the challenges and opportunities that lie ahead for the industry.
Context Matters, Inc., a leading provider of health economics data technology for the pharmaceutical industry, and IHS Markit (Nasdaq: INFO), a world leader in critical information, analytics and solutions, today announced the launch of PriceCurrents, the first integrated data product offering from the two organizations for the life sciences industry.
Strategic Investment to Fuel Service Growth to Meet High Market Demand
NEW YORK, NY – BURLINGTON, MA – October 11, 2016 – Context Matters, Inc., the leading provider of health economics data for pharmaceutical industry market access intelligence, and Decision Resources Group (DRG), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, today announced that DRG is the lead investor in Context Matters’ recently completed Series B funding round. In connection with this strategic investment, Context Matters and DRG will leverage each other’s unique capabilities, industry leading best practices, and deep relationships throughout the healthcare ecosystem to meet the high market demand for their services.
NEW YORK, July 1, 2013 -- Context Matters announces two key hires to enhance its data, technology and analytics platform product. Kermit E. Daniel, Ph.D. assumes the role of Chief Analytics Officer, while Travis Donia assumes the role of Director of Technology.
Despite Rising Pharmaceutical Industry Interest in Real World Outcomes, Few Patient-Reported Outcomes Are Included in Diabetes Clinical Trials According to a Context Matters/Pfizer Study
NEW ORLEANS, May 20, 2013 -- Despite rising interest in real world outcomes, a recent study performed by Context Matters and Pfizer demonstrates that less than ten percent of diabetes clinical trials conducted in the past decade included patient-reported outcomes (PROs) as part of their protocols.
Presented today at the 18th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference in New Orleans, the study analyzed nearly 650 Phase 3 and Phase 2/3 diabetes clinical trials from the clinicaltrials.gov database. Among these trials, only 7.4 percent (47 trials) included PROs as part of their assessment protocols.
"One of the current trends in the pharmaceutical industry is to track real world outcomes. However, in the area of diabetes, one of the most prevalent diseases in the United States, patient-reported outcomes, which are a commonly used real world assessment tool, were included in less than ten percent of clinical trial protocols since the year 2000," said Ashley Jaksa, MPH, director of data and analytics at Context Matters.
The study concluded that the development of a standardized clinical trial-specific tool that helps measure patient-reported outcomes might lead to wider incorporation of PROs in clinical trial protocols, in line with the interest in real world outcomes.
"Working with Context Matters has been a very valuable experience. In the past, it was difficult and time-consuming to collect this information, but their data curation procedures and analytics platform has allowed us to gain a quick, clear understanding of the use of PROs in diabetes clinical trials in the past decade, " Alexandra Barsdorf, associate director, PRO Centre of Excellence, Global Market Access, PCBU, Pfizer, Inc.
Reimbursement Risk Tracker Offers Unlimited Capacity to Address Strategic Questions of Reimbursement and R&D
NEW YORK, April 18, 2013 -- Context Matters announces that it will be an exhibitor at the BIO Conference, where it will be demonstrating its Reimbursement Risk Tracker™, a multi-dimensional data tool that provides a comprehensive picture of the reimbursement environment. The Reimbursement Risk Tracker allows the pharmaceutical and biotechnology industries to follow trends and gain strategic insight for multiple strategic applications. The product is an intuitive web-based data resource that highlights a variety of contexts, including clinical development, drug reimbursement, regulatory considerations and pricing. Context Matters can be found at Booth #3076 in the exhibition hall at the McCormick Center in Chicago.
"What's unique about our product is that it has an unlimited capacity to answer strategic questions, because it allows users to select whatever context is important to them," said Yin Ho, MD, MBA, founder and CEO of Context Matters. "The Reimbursement Risk Tracker goes so far beyond just R&D and strategic planning because it encompasses so many areas, from clinical development to reimbursement, regulatory, pricing and intellectual property, all in a very user friendly and easily accessible application that allows for easy navigation and comparison."
The Reimbursement Risk Tracker (RRT) consists of a series of user-navigated views. One view is a multi-dimensional search engine that allows users to filter and navigate through more than 1,300 reimbursement agency reviews for pharmaceutical products. It allows users to search by disease condition, geography, and time. Another view allows the user to make side-by-side comparisons of HTA reviews including access to the full depth of information, including patient-reported outcomes. Across the application, RRT provides users with other relevant disease condition information including global prevalence data, reimbursement decisions and methodologies, and an overview of disease conditions.
"Our customers have indicated that they use the application as a quick start whenever they begin working on a new disease condition. They also use it to easily conduct literature searches, including direct access to the source documents to find nuanced, disease-specific information," said Tom Dever, director of client relations for Context Matters. "We collaborate very closely with our customers so that we can ensure that our products not only provide the most comprehensive data-based information available, but also meet the specific needs of our customers in an intuitive and accessible way."
Context Matters, Inc. is the next generation of healthcare data analytics, focusing on risk assessment metrics for pharmaceutical and biotechnology products. Its data-driven, evidence-based Reimbursement Risk Tracker™ helps the pharmaceutical and biotechnology industries put drug development into context, through a carefully constructed data analytics tool that combines intelligently culled, curated data and metrics into the context of clinical, reimbursement, regulatory and economic factors. Context Matters' platform and approach result in more informed decision-making by allowing users to access and understand complex data that has never before been quantified or aggregated in a tailored, needs-based approach.
NEW YORK, April 8, 2013 -- Context Matters announces the addition of patient-reported outcomes (PROs) to its proprietary data platform, the Reimbursement Risk Tracker™, which provides pharmaceutical and biotechnology customers with unprecedented access to information for clinical development, drug reimbursement, regulatory considerations and pricing.
Recent Study Demonstrates Interchangeable Use of Terms That Rely on Different Circumstances
NEW YORK, Nov. 6, 2012 -- A recent global analysis of product evaluations for Health Technology Assessments – which are often influential in decision making for approving and/or providing reimbursement for pharmaceuticals and other medical technology – found that the use of the word "efficacy" and effectiveness" proved misleading in the context of reimbursement decisions, which may negatively affect their outcomes.
The study, presented at the International Society of Pharmacoeconomics and Outcomes Research conference in Berlin, suggests that while agencies state they are evaluating efficacy and effectiveness a similar number of times, their evaluations are generally for efficacy. This is important based on the actual meanings of the terms. Efficacy entails how a drug performs in an ideal or controlled circumstance, as in the context of a clinical trial. However, effectiveness describes a drug's success in real-world circumstances where the patient population and other variables cannot be controlled. Although reimbursement decisions are based on HTAs, the study demonstrated that the term effectiveness is often used when the evidence presented for consideration is often based on clinical trial scenarios rather than real world circumstances.
"These two terms have been used interchangeably for quite some time," said Yin Ho, MD, MBA, CEO of New York-based Context Matters, and co-author of the study. "However, the difference between them is a vital one to understand when making reimbursement decisions. It is even more surprising that so many of the HTAs that we evaluated interchanged the two terms, such that only one actually looked at effectiveness."
The study examined 38 HTAs from English-speaking countries, of which 20 stated they were evaluating effectiveness. Of the 20, only one actually evaluated real-world use of the drug. Conversely, 17 stated they were measuring efficacy and actually did so. Interestingly, the UK-based NICE and Scotland-based HIS were the two agencies of six that had the most discrepancy between the two terms.
The study was sponsored and performed by Context Matters, Inc.
Context Matters, Inc. is the next generation of healthcare data analytics, focusing on risk assessment metrics for pharmaceutical and biotechnology products. Its data-driven /evidence-based approach begins with our proprietary software database platform of intelligently culled, curated, and relevant business information and data to answer strategic business questions and provide actionable analysis. Its platform and approach result in more informed decision-making by allowing users to access and understand complex data that has never before been quantified or aggregated through a tailored, needs-based approach.